Zurit Levine Biography and Net Worth

Senior Vice President, Business Development of Compugen

Zurit was appointed as Senior Vice President, Business Development in 2025 after being Senior Vice President of Strategic Collaborations in 2024. Zurit is responsible for business development activities, identifying and establishing strategic partnerships, competitive market intelligence and leading Compugen’s IP strategy and portfolio. Zurit joined Compugen in 1999 and has held several positions with increasing responsibility in Compugen’s Research & Development department. In 2004, she was appointed as Director of Therapeutic Selection & Validation, a position she held until 2007 when she was appointed as Director of Therapeutic Discovery. In 2009, she was appointed as Executive Director of Research & Development. From January 2010 to August 2011, she held the position of Vice President, Research and Development. In August 2011, she was appointed as Vice President, Research and Discovery. In 2018, Zurit was appointed as Senior Vice President, Technology Innovation. Zurit holds a B.Sc. in Biology, an M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from Tel Aviv University.

What is Zurit Levine's net worth?: The estimated net worth of Zurit Levine is at least $69.18 thousand as of July 9th, 2026. Ms. Levine owns 29,375 shares of Compugen stock worth more than $69,178 as of July 16th. This net worth approximation does not reflect any other investments that Ms. Levine may own. Learn More about Zurit Levine's net worth.
How do I contact Zurit Levine?: The corporate mailing address for Ms. Levine and other Compugen executives is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. Compugen can also be reached via phone at (723) 765-8585 and via email at [email protected]. Learn More on Zurit Levine's contact information.
Has Zurit Levine been buying or selling shares of Compugen?: Within the last three months, Zurit Levine has sold $4,687.50 in Compugen stock. Most recently, Zurit Levine sold 1,875 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $2.50, for a transaction totalling $4,687.50. Following the completion of the sale, the senior vice president now directly owns 29,375 shares of the company's stock, valued at $73,437.50. Learn More on Zurit Levine's trading history.
Who are Compugen's active insiders?: Compugen's insider roster includes Zurit Levine (Senior Vice President, Business Development), and Eran Ophir (President and CEO). Learn More on Compugen's active insiders.
Are insiders buying or selling shares of Compugen?: In the last year, insiders at the biotechnology company sold shares 9 times. They sold a total of 34,000 shares worth more than $88,476.25. The most recent insider tranaction occured on July, 9th when SVP Zurit Levine sold 1,875 shares worth more than $4,687.50. Insiders at Compugen own 9.5% of the company. Learn More about insider trades at Compugen.
Information on this page was last updated on 7/9/2026.

Zurit Levine Insider Trading History at Compugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/9/2026	Sell	1,875	$2.50	$4,687.50	29,375
4/24/2026	Sell	2,000	$3.20	$6,400.00	29,375
4/10/2026	Sell	3,125	$2.56	$8,000.00	29,375
4/8/2026	Sell	5,375	$2.42	$13,007.50	29,375
4/7/2026	Sell	2,500	$2.30	$5,750.00	29,375
4/1/2026	Sell	3,500	$2.20	$7,700.00	29,375

Zurit Levine Buying and Selling Activity at Compugen

Compugen Company Overview

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Today's Range

Now: $2.35

$2.33

$2.43

50 Day Range

MA: $2.38

$1.96

$3.03

2 Week Range

Now: $2.35

$1.29

$3.23

Volume

104,933 shs

Average Volume

423,990 shs

Market Capitalization

$221.73 million

P/E Ratio

6.34

Dividend Yield

N/A

Beta

2.76